{"id":14924,"date":"2019-10-02T13:45:54","date_gmt":"2019-10-02T12:45:54","guid":{"rendered":"https:\/\/touchendocrinology.com\/?post_type=media_gallery&p=14924"},"modified":"2019-10-02T13:45:54","modified_gmt":"2019-10-02T12:45:54","slug":"jan-soupal-easd-2019-the-comisair-study","status":"publish","type":"media_gallery","link":"https:\/\/touchendocrinology.com\/diabetes\/conference-hub\/jan-soupal-easd-2019-the-comisair-study\/","title":{"rendered":"Jan Soupal, EASD 2019: The COMISAIR study"},"content":{"rendered":"
At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Jan Soupal<\/strong> discusses the latest data from the COMISAIR study.<\/p>\n Questions<\/strong> Jan Soupal has no conflicts of interest to declare in relation to this video.<\/p>\n Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.<\/strong><\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Jan Soupal discusses the latest data from the COMISAIR study. Questions 1. Could you tell us a little about the aims and design of the COMISAIR trial? (0:05) 2. What were the major findings of this study? (2:22) 3. What were […]<\/p>\n","protected":false},"featured_media":14886,"template":"","class_list":["post-14924","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-diabetes","video_categories-easd-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media_gallery\/14924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":0,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media_gallery\/14924\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media\/14886"}],"wp:attachment":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media?parent=14924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n1. Could you tell us a little about the aims and design of the COMISAIR trial? (0:05)
\n2. What were the major findings of this study? (2:22)
\n3. What were the limitations of this study and what future studies are planned? (2:58)
\n4. How have these findings changed the role of continuous glucose monitoring (CGM) and insulin delivery in the management of type 1 diabetes? (3:44)
\n5. What barriers exist to the wider utilisation of CGM and how may they be overcome? (4:16)<\/p>\n